Inhibition of nuclear factor-κB activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy

Kidney International

Volumn 63, Issue 1, 2003, Pages 306-314

  Tamada, Satoshi ^a,b   Nakatani, Tatsuya ^a,b   Asai, Toshihiro ^a,b   Tashiro, Koichiro ^a,b   Komiya, Toshiyuki ^a,b   Sumi, Tomohiko ^a,b   Okamura, Mikio ^a,b   Kim, Shokei ^a,b   Iwao, Hiroshi ^a,b   Kishimoto, Taketoshi ^a,b   Yamanaka, Shinya ^a,b   Miura, Katsuyuki ^a,b,c  

^a Osaka Prefecture University   (Japan)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antioxidant; Chronic nephropathy; Immunosuppression; Inflammation; Interstitial fibrosis; Monocyte macrophage infiltration; Nephrotoxicity; Tubular injury

Indexed keywords

CHEMOATTRACTANT; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PROTEIN; PYRROLIDINE DITHIOCARBAMATE; RNA; SODIUM; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DNA BINDING; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EXTRACELLULAR MATRIX; FEEDING; FIBROGENESIS; FIBROSING ALVEOLITIS; GENE EXPRESSION; GLOMERULUS FILTRATION; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TUBULE; KIDNEY TUBULE DAMAGE; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM RESTRICTION; UPREGULATION;

EID: 6444245024     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00714.x     Document Type: Article

References (34)

1. Young BA, Burdmann EA, Johnson RJ, et al: Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 48:439-448, 1995
2. Asai T, Nakatani T, Yamanaka S, et al: Magnesium supplementation prevents experimental chronic cyclosporine A nephrotoxicity via reninangiotensin system independent mechanism. Transplantation 74:784-791, 2002
3. Rodriguez-Iturbe B, Pons H, Herrera-Acosta J, et al: Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 59:1626-1640, 2001
4. Morrissey JJ, Klahr S: Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol 274:F580-F586, 1998
5. Taal MW, Zandi-Nejad K, Weening B, et al: Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int 58:1664-1676, 2000
6. Kovacs EJ: Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol Today 12:17-23, 1991
7. Barnes PJ, Karin M: Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071, 1997
8. Guijarro C, Egido J: Transcription factor-κB (NF-κB) and renal disease. Kidney Int 59:415-424, 2001
9. Yoshimura T, Takeya M, Takahashi K: Molecular cloning of rat monocyte chemoattractant protein-1 (MCP-1) and its expression in rat spleen cells and tumor cell lines. Biochem Biophys Res Commun 174:504-509, 1991
10. Ueda A, Okuda K, Ohno S, et al: NF-κB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 153:2052-2063, 1994
11. Miura K, Nakatani T, ASAI T, et al: Role of hypomagnesemia in chronic cyclosporine nephropathy. Transplantation 73:340-347, 2002
12. Seto M, Kim S, Yoshifusa H, et al: Effects of prednisolone on glomerular signal transduction cascades in experimental glomerulonephritis. J Am Soc Nephrol 9:1367-1376, 1998
13. Baldwin AS Jr: The NF-κB and I-κB proteins: New discoveries and insights. Annu Rev Immunol 14:649-683, 1996
14. Meyer M, Caselmann WH, Schluter V, et al: Hepatitis B virus transactivator MHBst: Activation of NF-κB, selective inhibition by antioxidants and integral membrane localization. EMBO J 11:2991-3001, 1992
15. Liu SF, Ye X, Malik AB: Inhibition of NF-κB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 100:1330-1337, 1999
16. Oldberg A, Franzen A, Heinegard D: Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 83:8819-8823, 1986
17. Laiho M, Saksela O, Keski-Oja J: Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem 262:17467-17474, 1987
18. Shihab FS, Bennett WM, Tanner AM, et al: Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 64:1829-1837, 1997
19. Frantz B, Nordby EC, Bren G, et al: Calcineurin acts in synergy with PMA to inactivate I-κB/MAD3, an inhibitor of NF-κB. EMBO J 13:861-870, 1994
20. Holschermann H, Durfeld F, Maus U, et al: Cyclosporine inhibits tissue factor expression in monocytes/macrophages. Blood 88:3837-3845, 1996
21. Kunz D, Walker G, Eberhardt W, et al: Interleukin 1 beta-induced expression of nitric oxide synthase in rat renal mesangial cells is suppressed by cyclosporin A. Biochem Biophys Res Commun 216:438-446, 1995
22. Kaibori M, Sakitani K, Oda M, et al: Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF-κB activation in rat hepatocytes. J Hepatol 30:1138-1145, 1999
23. Pahl HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18:6853-6866, 1999
24. Andoh TF, Burdmann EA, Lindsley J, et al: Functional and structural characteristics of experimental FK 506 nephrotoxicity. Clin Exp Pharmacol Physiol 22:646-654, 1995
25. Burdmann EA, Andoh TF, Nast CC, et al: Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 269:F491-F499, 1995
26. Shihab FS, Bennett WM, Tanner AM, et al: Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 52:660-673, 1997
27. Nakatani T, Uchida J, Asai T, et al: Effect of tacrolimus on the gene expression of renin and endothelin in the rat kidney. Transplant Proc 33:2296-2297, 2001
28. Bowie A, O'Neill LA: Oxidative stress and nuclear factor-κB activation: A reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59:13-23, 2000
29. Wang C, Salahudeen AK: Cyclosporine nephrotoxicity: Attenuation by an antioxidant-inhibitor of lipid peroxidation in vitro and in vivo. Transplantation 58:940-946, 1994
30. Wang C, Salahudeen AK: Lipid peroxidation accompanies cyclosporine nephrotoxicity: Effects of vitamin E. Kidney Int 47:927-934, 1995
31. Zhang Y, Sun X, Muraoka K, et al: Immunosuppressant FK506 activates NF-κB through the proteasome-mediated degradation of IκBα. Requirement for IκBα n-terminal phosphorylation but not ubiquitination sites. J Biol Chem 274:34657-34662, 1999
32. Ross SD, Kron IL, Gangemi JJ, et al: Attenuation of lung reperfusion injury after transplantation using an inhibitor of nuclear factor-κB. Am J Physiol Lung Cell Mol Physiol 279:L528-L536, 2000
33. Topping RJ, Jones MM: Optimal dithiocarbamate structure for immunomodulator action. Med Hypotheses 27:55-57, 1988
34. Beswick RA, Zhang H, Marable D, et al: Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37:781-786, 2001